MGC Pharmaceuticals Limited – LSE:MXC.L

MGC Pharmaceuticals Limited stock price today

GBP 1.175
-20.02
-94.46%
Financial Health
0
1
2
3
4
5
6
7
8
9

MGC Pharmaceuticals Limited stock price monthly change

+14.59%
month

MGC Pharmaceuticals Limited stock price quarterly change

-21.48%
quarter

MGC Pharmaceuticals Limited stock price yearly change

+4244.26%
year

MGC Pharmaceuticals Limited key metrics

Market Cap
 9.29M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -10.54
Revenue
 5.97M
EBITDA
 -21.47M
Income
 -28.70M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 -359.61%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

MGC Pharmaceuticals Limited stock price history

MGC Pharmaceuticals Limited stock forecast

MGC Pharmaceuticals Limited financial statements

Profit Margin

MGC Pharmaceuticals Limited (LSE:MXC.L): Profit margin
Sep 2021 1.29M -3.94M -305.26%
Dec 2021 1.29M -3.94M -305.26%
Dec 2022 2.66M -10.88M -408.7%
Jun 2023 724.92K -9.94M -1371.38%
MXC.L income statement history

MGC Pharmaceuticals Limited Financials Estimate

MGC Pharmaceuticals Limited (LSE:MXC.L): Analyst Estimates
2026 23.88M -58.18M -243.57%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

MGC Pharmaceuticals Limited (LSE:MXC.L): Debt to assets
Sep 2021 30031932 11.66M 38.85%
Dec 2021 30031932 11.66M 38.85%
Sep 2022 15243200 18.13M 118.94%
Dec 2022 15243200 18.13M 118.94%
MXC.L balance sheet history

Cash Flow

MGC Pharmaceuticals Limited (LSE:MXC.L): Cash Flow
Dec 2020 -2.92M -78.80K 2.83M
Dec 2021 -5.39M -1.80M 9.81M
Dec 2022 -6.75M 533.84K 5.45M
Jun 2023 -5.23M 72.34K 4.27M
MXC.L cash flow history

MGC Pharmaceuticals Limited other data

Frequently Asked Questions (FAQ)

  • What's the price of MGC Pharmaceuticals Limited stock today?

    One share of MGC Pharmaceuticals Limited stock can currently be purchased for approximately $1.18.

  • When is MGC Pharmaceuticals Limited's next earnings date?

    Unfortunately, MGC Pharmaceuticals Limited's (MXC.L) next earnings date is currently unknown.

  • Does MGC Pharmaceuticals Limited pay dividends?

    No, MGC Pharmaceuticals Limited does not pay dividends.

  • How much money does MGC Pharmaceuticals Limited make?

    MGC Pharmaceuticals Limited has a market capitalization of 9.29M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 57.94% to 4.73M US dollars.

  • What is MGC Pharmaceuticals Limited's stock symbol?

    MGC Pharmaceuticals Limited is traded on the LSE under the ticker symbol "MXC.L".

  • What is MGC Pharmaceuticals Limited's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of MGC Pharmaceuticals Limited?

    Shares of MGC Pharmaceuticals Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • When MGC Pharmaceuticals Limited went public?

    MGC Pharmaceuticals Limited is publicly traded company for more then 4 years since IPO on 9 Feb 2021.

  • What is MGC Pharmaceuticals Limited's official website?

    The official website for MGC Pharmaceuticals Limited is mgcpharma.com.au.

  • Where are MGC Pharmaceuticals Limited's headquarters?

    MGC Pharmaceuticals Limited is headquartered at 1202 Hay Street, West Perth, WA.

  • How can i contact MGC Pharmaceuticals Limited?

    MGC Pharmaceuticals Limited's mailing address is 1202 Hay Street, West Perth, WA and company can be reached via phone at +61 8 6382 3390.

MGC Pharmaceuticals Limited company profile:

MGC Pharmaceuticals Limited

mgcpharma.com.au
Exchange:

LSE

Full time employees:

0

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.

+61 8 6382 3390
1202 Hay Street
West Perth, WA 6005

:
ISIN: AU000000MXC6
: